Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • Arabic
      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Overview
  • Distribution by PR Newswire
  • AI Tools
  • Multichannel Amplification
  • Guaranteed Paid Placement
  • SocialBoost
  • All Products
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • Overview
  • Distribution by PR Newswire
  • AI Tools
  • Multichannel Amplification
  • SocialBoost
  • All Products
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS

Lilly Oncology On Canvas: Expressions of a Cancer Journey Reaches Important Milestone With 2014 Competition

Eli Lilly and Company logo. (PRNewsFoto, Eli Lilly and Company) (PRNewsFoto/ELI LILLY AND COMPANY)

News provided by

Eli Lilly and Company

Jan 08, 2014, 12:17 ET

Share this article

Share toX

Share this article

Share toX

INDIANAPOLIS, Jan. 8, 2014 /PRNewswire/ -- Some see paint. Others see hope. What do you see? Ten years ago, more than 400 people across 23 countries saw those words and shared their cancer journeys with the world through art and narrative. While more than 4,100 stories have been shared, there are many still waiting to be told. In the U.S.[i] there are nearly 14 million cancer survivors today in addition to millions of others who love and care for them. Creating, viewing and talking about the disease can help patients and their loved ones cope with this serious illness.

Continue Reading
Lilly Oncology. (PRNewsFoto/Eli Lilly and Company) (PRNewsFoto/ELI LILLY AND COMPANY)
Lilly Oncology. (PRNewsFoto/Eli Lilly and Company) (PRNewsFoto/ELI LILLY AND COMPANY)
Lilly Oncology On Canvas Celebrating 10 Years. (PRNewsFoto/Eli Lilly and Company) (PRNewsFoto/ELI LILLY AND COMPANY)
Lilly Oncology On Canvas Celebrating 10 Years. (PRNewsFoto/Eli Lilly and Company) (PRNewsFoto/ELI LILLY AND COMPANY)
National Coalition For Cancer Survivorship. (PRNewsFoto/Eli Lilly and Company) (PRNewsFoto/ELI LILLY AND COMPANY)
National Coalition For Cancer Survivorship. (PRNewsFoto/Eli Lilly and Company) (PRNewsFoto/ELI LILLY AND COMPANY)

Lilly Oncology and the National Coalition for Cancer Survivorship (NCCS) today announced the launch of the 2014 Lilly Oncology On Canvas: Expressions of a Cancer Journey Art Competition and Exhibition. The biennial competition invites individuals from the United States and Puerto Rico, who were diagnosed with any type of cancer – as well as their families, friends, caregivers and healthcare providers – to express, through art and narrative, the life-affirming changes that give their cancer journeys meaning. The deadline for entries is June 30, 2014.

The 2014 competition marks the 10th anniversary of Lilly Oncology On Canvas. In honor of this milestone, Lilly Oncology will be launching the Hope Murals Project, bringing 10 inspirational pieces of art to 10 cities, in the form of 10 murals. Information on the Hope Murals Project, additional anniversary activities, previous years' entries, details on the 2014 Lilly Oncology On Canvas competition, official rules and regulations and a downloadable entry form — may be found on www.LillyOncologyOnCanvas.com.

"The year 2014 marks an important milestone for Lilly Oncology On Canvas," said Newt Crenshaw, vice president, Lilly Oncology. "In the last decade, we have watched Oncology On CanvasSM become a vital platform for cancer patients, oncologists, oncology nurses and so many others to share their cancer journeys. We are excited to celebrate this anniversary and the thousands of people the competition has touched."

Oncology On Canvas was launched in 2004 by Lilly Oncology to help those affected by cancer cope with the emotional side of the disease. Winners' prizes consist of donations made to the cancer charities of their choice. Following the competition, select artwork embarks on a tour of cancer centers, hospitals and patient advocacy group events. The last decade has also provided additional platforms on which to share Oncology On Canvas artwork, most recently, Pinterest.

"The personal stories and insights cancer patients and those who love and care for them share through their Lilly Oncology On Canvas entries never fail to move me and everyone I know who experiences them, whether in person at exhibitions or virtually on the website, or even flipping through the artbook at a cancer clinic," said Nina Wendling, executive director, NCCS. "NCCS is proud to continue its decade-long partnership with Lilly and looks, with great anticipation, to this competition year's entries."   

Call for Entries
The 2014 Lilly Oncology On Canvas Art Competition is open to residents of the United States and Puerto Rico in three categories: person diagnosed with cancer; family member, friend or caregiver; and healthcare professional. Original artwork that depicts one's cancer journey may be submitted in one of six media: watercolor, oil, pastel, photography, acrylic or mixed media. The artwork must be accompanied by a narrative. The competition, exhibition, and awards are subject to certain laws and regulations, which may prevent some individuals (e.g., healthcare practitioners and government officials) from accepting the awards, benefits and/or acknowledgements associated with this program.  

Winners in 17 categories will be chosen by an independent panel of judges. Prizes consist of donations to cancer-related charities selected by the winners, ranging from $1,000 to $10,000. Following the competition, much of the artwork will embark on a tour of cancer centers, hospitals and patient advocacy group events throughout the United States and Puerto Rico.  

For further information about Lilly Oncology On Canvas visit www.LillyOncologyOnCanvas.com. You may also call 1-866-991-LOOC (5662) or e-mail [email protected]. You can follow Lilly Oncology On Canvas on:

  • Twitter (www.twitter.com/LlyOncOnCanvas),
  • Facebook (www.facebook.com/LillyOncologyOnCanvas),
  • Pinterest (www.pinterest.com/LlyOncOnCanvas)
  • YouTube (www.youtube.com/LlyOncOnCanvas).

To learn more about cancer survivorship tools and resources, visit the National Coalition for Cancer Survivorship (NCCS) website at www.canceradvocacy.org.

About the National Coalition for Cancer Survivorship 
Founded by and for cancer survivors, the National Coalition for Cancer Survivorship (NCCS) advocates for quality cancer care for all people touched by cancer and provides tools and resources that empower people to advocate for themselves. NCCS believes patients empowered with information can receive optimal care by making their needs known to their doctors and care teams. NCCS strongly believes in evidence-based advocacy that reflects the needs of all cancer survivors to affect policy change at the national level. By advocating for patient-centered, coordinated care through treatment planning and care planning, NCCS is ensuring that the needs of cancer survivors remain at the center of healthcare policy. Since 2004, NCCS has been the co-presenter of the Lilly Oncology On Canvas Art Competition and Exhibition. NCCS offers publications and resources such as the award-winning Cancer Survival Toolbox®, a self-learning audio program created by leading cancer organizations to help people develop essential skills to meet the challenges of their illness. More information is available at www.canceradvocacy.org or 1-888-650-9127.

About Lilly Oncology
For more than five decades, Lilly Oncology, a division of Eli Lilly and Company (NYSE: LLY), has been dedicated to delivering innovative solutions that improve the care of people living with cancer. Because no two cancer patients are alike, Lilly Oncology is committed to developing novel treatment approaches. To learn more about Lilly's commitment to cancer, please visit www.LillyOncology.com.

About Eli Lilly and Company
Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers —through medicines and information— for some of the world's most urgent medical needs. 

P-LLY

[i] American Cancer Society, Cancer Facts & Figures 2013, http://www.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2013/index. Accessed June 27, 2013. 

Refer to:

Keri McGrath (Lilly)

Dennis da Costa (TogoRun)


Phone: 317-370-8394

Phone: 212-453-2461 


Mobile: 317 277 3768

Mobile: 914-645-7553 


[email protected]

[email protected]

(Logo: http://photos.prnewswire.com/prnh/20031219/LLYLOGO )

(Logo:  http://photos.prnewswire.com/prnh/20140108/DE42322LOGO-a )

(Logo:  http://photos.prnewswire.com/prnh/20140108/DE42322LOGO-b )

(Logo:  http://photos.prnewswire.com/prnh/20140108/DE42322LOGO-c )

SOURCE Eli Lilly and Company

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

icon3
440k+
Newsrooms &
Influencers
icon1
9k+
Digital Media
Outlets
icon2
270k+
Journalists
Opted In
GET STARTED

Modal title

Also from this source

Lilly's Jaypirca (pirtobrutinib), the first and only approved non-covalent (reversible) BTK inhibitor, significantly improved progression-free survival in patients with treatment-naïve CLL/SLL

Lilly's Jaypirca (pirtobrutinib), the first and only approved non-covalent (reversible) BTK inhibitor, significantly improved progression-free survival in patients with treatment-naïve CLL/SLL

Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the Phase 3 BRUIN CLL-313 clinical trial of Jaypirca (pirtobrutinib), ...

Lilly's olomorasib receives U.S. FDA's Breakthrough Therapy designation for the treatment of certain newly diagnosed metastatic KRAS G12C-mutant lung cancers

Lilly's olomorasib receives U.S. FDA's Breakthrough Therapy designation for the treatment of certain newly diagnosed metastatic KRAS G12C-mutant lung cancers

Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to...

More Releases From This Source

Explore

Medical Pharmaceuticals

Medical Pharmaceuticals

Art

Art

Pharmaceuticals

Pharmaceuticals

Corporate Social Responsibility

Corporate Social Responsibility

News Releases in Similar Topics

Contact PR Newswire

  • Call PR Newswire at 888-776-0942
    from 8 AM - 9 PM ET
  • Chat with an Expert
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Italy
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • Vietnam

My Services

  • All New Releases
  • Platform
  • ProfNet
  • Data Privacy

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Platform
  • ProfNet
Call PR Newswire at
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookies
Copyright © 2025 Cision US Inc.